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ABSTRACT: Mycobacteria, including the pathogen
Mycobacterium tuberculosis, use the non-mammalian
disaccharide trehalose as a precursor for essential cell-
wall glycolipids and other metabolites. Here we describe a
strategy for exploiting trehalose metabolic pathways to
label glycolipids in mycobacteria with azide-modified
trehalose (TreAz) analogues. Subsequent bioorthogonal
ligation with alkyne-functionalized probes enabled detec-
tion and visualization of cell-surface glycolipids. Character-
ization of the metabolic fates of four TreAz analogues
revealed unique labeling routes that can be harnessed for
pathway-targeted investigation of the mycobacterial
trehalome.
Mycobacterium tuberculosis (Mtb), the causative agent of
tuberculosis, currently infects 2 billion people worldwide and
causes approximately 2 million deaths annually.1 The success of
Mtb as a pathogen is in large part due to its complex cell wall,
which is a formidable barrier to antibiotics and residence to
many biomolecules that are directly involved in pathogenesis.
The mycobacterial cell wall features a unique outer
membranethe “mycomembrane” (MM)that is composed
of long-chain (C60−C90) mycolic acids covalently bound to the
underlying peptidoglycan−arabinogalactan polymer, as well as
an array of additional free intercalating lipids and glycolipids.2,3
Trehalose-containing glycolipids are abundant, virulence-
associated constituents of the MM that have essential roles in
cell-wall biosynthesis and disease progression. Trehalose mono-
and dimycolate (TMM and TDM), bearing 6-O- and 6,6′-di-O-
mycolyl substituents, respectively, are produced by all
mycobacterial species (Figure 1A). TMM is an essential
mediator of MM biosynthesis4−6 (see Figure 2) and is also
the precursor to TDM, an immunomodulatory molecule that
promotes Mtb infectivity and survival within host macro-
phages.7−9 Along with TMM and TDM, numerous other
complex metabolites constitute the mycobacterial “trehalome.”
Unfortunately, the various roles played by these metabolites in
Mtb physiology and pathogenesis are challenging to study using
traditional genetic and biochemical methods, which generally
require laborious radiolabeling, extraction, and purification
procedures that are incompatible with in vivo experimentation.
Metabolic labeling with unnatural sugar substrates is a
powerful alternative for investigating glycoconjugates in living
organisms.10 Here we report that trehalose glycolipids can be
metabolically labeled with azide-modified trehalose (TreAz)
analogues (Figure 1B) in live mycobacteria, enabling
bioorthogonal ligation with alkyne-functionalized fluorescent
probes (Figure 1C). We capitalized on the conserved pathways
for mycobacterial trehalose metabolism shown in Figure 2.
While trehalose glycolipids reside in the MM, they originate in
the cytoplasm, where free trehalose is synthesized through
metabolic cycles involving either glucose (via the OtsAB/
trehalase enzymes) or α-glucans (via the TreYZ/TreS
enzymes).11−14 Trehalose and mycolic acid combine in the
cytoplasm to form TMM, which is then translocated across the
plasma membrane by MmpL3.5,6 Subsequently, the antigen 85
(Ag85) complex mediates the transfer of mycolate from TMM
to either arabinogalactan, which forms covalently bound
mycolates that make up the foundation of the MM, or to
another molecule of TMM, which generates TDM.15,16 Both
processes release free trehalose, which is recycled by the
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Figure 1. (A) Common trehalose glycolipids in mycobacteria. (B)
Synthetic TreAz analogues used in this study. (C) TreAz-based
bioorthogonal chemical reporter strategy.
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trehalose-specific transporter SugABC-LpqY.4 Species-depend-
ent metabolic pathways (not shown in detail) can generate a
range of additional metabolites in Mtb and other mycobacteria.
In recent work, Backus et al. demonstrated that a fluorescein-
conjugated keto-trehalose analogue (FITC-Tre) is incorporated
into TDM via the Ag85 complex.17 This observation under-
scores one possible route by which unnatural substrates might
access trehalose glycolipids: after crossing through the MM,
likely by a porin-mediated process,18 the unnatural analogue
could be processed by Ag85 and incorporated into TMM or
TDM outside of the cell (Figure 2, orange dotted arrow).
Alternatively, labeling could occur via the trehalose recycling
pathway, in which analogues would be internalized by the
SugABC-LpqY transporter and incorporated into glycolipids
from the inside-out (Figure 2, blue dotted arrow). Access to the
recycling pathway has not been reported for any chemical
probes to date but is essential for investigating processes that
originate in the cytoplasm, such as de novo biosynthesis of
glycolipids and MM, as well as species-dependent trehalose
metabolism.
We hypothesized that TreAz analogues, in which a hydroxyl
group is replaced with a relatively small, minimally perturbing
azido group, would be well-tolerated by the mycobacterial
biosynthetic machinery, allowing unprecedented access to the
trehalose recycling pathway. In addition, the modular nature of
bioorthogonal ligation affords numerous advantages over other
labeling strategies, including choice of bioorthogonal reaction
and probe type, temporal control of probe delivery (permitting
pulse-chase biological experiments19), and the ability to
minimize background signal by use of low probe concen-
trations.
We synthesized a series of trehalose analogues containing
azido groups at all possible positions with native stereo-
chemistry [Figure 1B; refer to the Supporting Information (SI)
for schemes and procedures]. The compounds were initially
evaluated for metabolic incorporation into glycolipids in the
model organism M. smegmatis mc2155 (Msmeg). Briefly,
bacteria were cultured with TreAz until logarithmic phase
(typically 12−16 h), then reacted with BARAC-Fluor (1 μM,
30 min), a fluorescein-conjugated biarylazacyclooctynone used
for rapid Cu-free click chemistry.20 Analysis by flow cytometry
revealed that all four TreAz analogues labeled Msmeg, albeit
with different efficiencies (Figure 3A). 2- and 6-TreAz labeled
cells robustly at low concentrations (5−25 μM), while labeling
with 3- and 4-TreAz required higher concentrations (250−500
μM). At these doses, no changes in bacterial growth were
observed. The described flow cytometry assay was also used to
evaluate the dependence of Msmeg labeling on analogue
concentration, culture time, and exogenously added free
trehalose (i.e., competition studies; Figures S1−S3).
Next, fluorescence microscopy was used to visualize azide-
bearing cell-surface glycolipids (Figure 3B). Msmeg was
cultured with TreAz, fixed, and then reacted with alkyne-
functionalized Alexa Fluor 48821 (alk-AF488) via Cu(I)-
catalyzed azide−alkyne cycloaddition (CuAAC).22,23 For all
TreAz analogues, azide-specific fluorescence was observed
uniformly throughout the bacterial population, and signal was
predominantly localized to the cell surface, which is in
Figure 2. Trehalose metabolism in mycobacteria. Exogenous TreAz
can label glycolipids via the Ag85 or recycling pathways. AG,
arabinogalactan; CL, capsular layer; MM, mycomembrane; PG,
peptidoglycan; PM, plasma membrane. Exact extracellular location of
Ag85 is unknown.
Figure 3. (A) Flow cytometry analysis of TreAz-labeled Msmeg reacted
with BARAC-Fluor. Error bars denote the standard deviation of three
replicate experiments. (B) Fluorescence microscopy of TreAz-labeled
Msmeg reacted with alk-AF488 via CuAAC. Scale bars, 5 μm.
Journal of the American Chemical Society Communication
dx.doi.org/10.1021/ja3062419 | J. Am. Chem. Soc. 2012, 134, 16123−1612616124
agreement with glycolipids inhabiting the MM. Interestingly,
fluorescence was frequently concentrated at the bacterial poles,
consistent with a polar growth model for mycobacteria.24
In addition to fluorescence detection, we directly charac-
terized TreAz-labeled glycolipids by chemical methods. Analysis
of partially purified chloroform−methanol lipid extracts by
TLC and high-resolution mass spectrometry confirmed that all
four TreAz analogues produced azide-labeled glycolipids in
Msmeg (Figure S4). To provide further direct evidence that
TreAz was incorporated into glycolipids, petroleum ether lipid
extracts from Msmeg cultured with 2- or 6-TreAz (or vehicle)
were deacylated by treatment with NaOMe at 60 °C. The
released free sugars were analyzed by high-pH anion exchange
chromatography with pulsed amperometric detection
(HPAEC-PAD), which showed peaks for 2- and 6-TreAz in
the corresponding samples but not in vehicle-treated or non-
deacylated control samples (Figure S5). Comparison of peak
integrations indicated that 2- and 6-TreAz replaced approx-
imately 20% and 70% of natural trehalose, respectively, in
surface-exposed glycolipids extracted from TreAz-treated cells.
To establish whether TreAz incorporation into glycolipids
occurred via the Ag85 or recycling pathway, azide labeling was
evaluated in the Msmeg mutants ΔsugC and ΔlpqY, which lack
the trehalose transporter,4 by reaction with BARAC-Fluor
followed by flow cytometry (Figure 4A). Fluorescence observed
for 2-, 4-, and 6-TreAz in the wild-type strain was completely
abolished in the mutants, demonstrating that metabolic labeling
of glycolipids using these analogues requires uptake into the
cytoplasm and proceeds through the recycling pathway. In
contrast, labeling with 3-TreAz was not reduced in the
transporter mutants, indicating that this compound likely
undergoes extracellular incorporation into glycolipids via Ag85,
similar to FITC-Tre.17
To confirm that 2-, 4-, and 6-TreAz enter the cytoplasm,
HPAEC-PAD was used to assess the presence of these
analogues in cytosolic extracts. As expected, 2-, 4-, and 6-
TreAz were observed in extracts from wild-type Msmeg, while
3-TreAz was not (Figure 4B); identically prepared samples
from the ΔsugC mutant showed no cytosolic TreAz (Figure
S6). Taken together, these data reveal that our TreAz analogues
have the capacity to selectively label trehalose-containing
metabolites via the Ag85 or recycling pathways, and thus
provide a platform for pathway-targeted probing of the
trehalome.
Our finding that 2-, 4-, and 6-TreAz enter the cell through
the recycling pathway in Msmeg raises the possibility that these
compounds might also be processed by trehalase or TreS
(Figure 2). We sought address whether these enzymes affect
cell-surface labeling, either by diverting TreAz into cell-surface
α-glucan (via TreS) or by degrading TreAz (via trehalase).
Msmeg ΔtreS14 and ΔMSMEG_4535 (trehalase) mutants were
generated (see SI) and evaluated for TreAz labeling compared
to wild-type Msmeg (Figures S7−S11). For the most part, no
significant differences were observed in the mutants, ruling out
any effects on cell-surface labeling by these enzymes. However,
we did observe a TreS-dependency for 4-TreAz labeling in
Msmeg (Figure S8). We are currently investigating the
intriguing possibility that TreAz analogues are incorporated
into cell-surface α-glucan, an experimentally elusive25 cell-wall
structure that has been implicated in immune evasion.14,26
Finally, we tested the TreAz analogues in pathogenic
mycobacteria. Mtb H37Rv and the closely related avirulent
species M. bovis BCG-Pasteur (BCG) were assessed by flow
cytometry as described above for Msmeg, and all four
compounds led to significant TreAz-dependent fluorescence
in both species (Figure 5A). We also generated a BCG mutant
ΔlpqY-sugC missing the trehalose transporter and its
corresponding complemented strain (see SI) to test the route
of TreAz labeling (Figure 5B). Consistent with the results from
Msmeg, 2- and 6-TreAz labeling was substantially reduced in the
Figure 4. (A) Flow cytometry analysis of TreAz-labeled Msmeg strains.
Error bars denote the standard deviation from three replicate
experiments. * p < 0.05. (B) HPAEC-PAD analysis of cytosolic
extracts from TreAz-treated wild-type Msmeg. Dotted lines represent
retention times for authentic standards (see SI for details).
Figure 5. Flow cytometry analysis of TreAz-labeled Mtb and BCG
strains. (A) Wild-type Mtb H37Rv and BCG; (B) wild-type BCG,
BCG ΔlpqY-sugC, and the corresponding complemented strain. Error
bars denote the standard deviation from three replicate experiments.
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mutant, suggesting that a recycling pathway mechanism for
these analogues may be conserved across mycobacterial species.
Also in agreement with data from Msmeg, 3-TreAz labeling was
unaffected in the mutant, indicating that selective incorporation
of this analogue by Ag85 is also conserved. 4-TreAz labeling,
which proceeded via the recycling pathway in Msmeg, instead
appeared to primarily use Ag85 in BCG. These results
confirmed that pathway-targeted TreAz labeling can be
extended to other mycobacteria, including pathogenic Mtb.
In summary, metabolic labeling with TreAz enables inter-
rogation of the trehalome in live mycobacteria. We showed that
all four TreAz analogues were effective in Msmeg, BCG, and
Mtb, and distinct routes of TreAz metabolismmostly
conserved across specieswere elucidated through genetic
and chemical techniques. This strategy can be used for imaging
glycolipid distribution, trafficking, and dynamics as well as
metabolite profiling and discovery. As well, the compounds
may be employed to assess the effects of various perturbations
(e.g., environmental stress, antibiotic treatment, genetic
manipulation) on trehalose glycolipids and their associated
biosynthetic pathways. We also expect that TreAz analogues
will be metabolized in other mycobacterial species given the
highly conserved nature of the involved biosynthetic machinery.
Importantly, the absence of trehalose metabolism in mammals
invites the application of this chemical tool to investigate the
trehalome during mycobacterial infection in host cells and
model organisms.
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